ECRG2 enhances the anti-cancer effects of cisplatin in cisplatin-resistant esophageal cancer cells via upregulation of p53 and downregulation of PCNA

Figure 4 Effects of esophageal cancer-related gene 2 combined with cisplatin (DDP) on cell apoptosis in EC9706/DDP cells. Cells were treated with esophageal cancer-related gene 2 (ECRG2) (6.5 μg/mL) alone, DDP (3 μg/mL) alone, or a combination of ECRG2 and DDP for 24 h. Early apoptosis was determined by flow cytometry using annexin V/PI staining. Annexin V was set as the horizontal axis and PI was set as the vertical axis. Mechanically-damaged cells are located in the upper left quadrant, apoptotic or necrotic cells in the upper right quadrant, dual negative and normal cells in the lower left quadrant, and early apoptotic cells in the lower right quadrant of the flow cytometry dot plot. Data are shown as the mean ± SD. ^aP < 0.05 vs control group; ^cP < 0.05 ECRG2 +DDP vs DDP; ^eP < 0.05 ECRG2 + DDP vs ECRG2.